Abstract. The Epstein-Barr virus (EBV) lytic cycle contributes to the development of EBV-associated diseases. EBV-encoded latent membrane protein 1 (LMP1) is key to EBV lytic replication, and our previous work indicated that epigallocatechin-3-gallate (EGCG) inhibited constitutive EBV lytic infectio

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Differentiation-Dependent LMP1 Expression Is Required for Efficient Lytic Epstein-Barr Virus Reactivation in Epithelial Cells

  2017influential reference
• Epstein-Barr virus lytic reactivation regulation and its pathogenic role in carcinogenesis

  2016cited by this paper
• LMP1-Induced Sumoylation Influences the Maintenance of Epstein-Barr Virus Latency through KAP1

  2015cited by this paper
• Maintenance of Epstein-Barr Virus Latent Status by a Novel Mechanism, Latent Membrane Protein 1-Induced Interleukin-32, via the Protein Kinase Cδ Pathway

  2015cited by this paper
• Comprehensive High-Throughput RNA Sequencing Analysis Reveals Contamination of Multiple Nasopharyngeal Carcinoma Cell Lines with HeLa Cell Genomes

  2014cited by this paper
• Switching of EBV cycles between latent and lytic states

  2014cited by this paper
• Targeting Epstein–Barr virus oncoprotein LMP1-mediated glycolysis sensitizes nasopharyngeal carcinoma to radiation therapy

  2014cited by this paper
• Regulation of the latent-lytic switch in Epstein-Barr virus.

  2014influential reference
• The role of Epstein–Barr virus in epithelial malignancies

  2014cited by this paper
• Regulation of Epstein–Barr virus reactivation from latency

  2014cited by this paper
• Therapeutic Evaluation of Epstein-Barr Virus-encoded Latent Membrane Protein-1 Targeted DNAzyme for Treating of Nasopharyngeal Carcinomas

  2013cited by this paper
• Replication of Epstein-Barr viral DNA.

  2013cited by this paper
• (-)-Epigallocatechin-3-gallate inhibition of Epstein-Barr virus spontaneous lytic infection involves ERK1/2 and PI3-K/Akt signaling in EBV-positive cells.

  2013cited by this paper
• Cancer therapy combination: green tea and a phosphodiesterase 5 inhibitor?

  2013cited by this paper
• EBV lytic infection enhances transformation of B‐lymphocytes infected with EBV in the presence of T‐lymphocytes

  2012cited by this paper
• The role of the EBV-encoded latent membrane proteins LMP1 and LMP2 in the pathogenesis of nasopharyngeal carcinoma (NPC).

  2012influential reference
• Recent advances on tea polyphenols.

  2012cited by this paper
• Epstein-Barr Virus: An Important Vaccine Target for Cancer Prevention

  2011cited by this paper
• Down-Regulation of EBV-LMP1 Radio-Sensitizes Nasal Pharyngeal Carcinoma Cells via NF-κB Regulated ATM Expression

  2011cited by this paper
• Chemoprevention of Head and Neck Cancer with Green Tea Polyphenols

  2010cited by this paper
• A New Model of Epstein-Barr Virus Infection Reveals an Important Role for Early Lytic Viral Protein Expression in the Development of Lymphomas

  2010cited by this paper
• Epigallocatechin-3-gallate, a histone acetyltransferase inhibitor, inhibits EBV-induced B lymphocyte transformation via suppression of RelA acetylation.

  2009cited by this paper
• Regulation of cellular and viral protein expression by the Epstein-Barr virus transcriptional regulator Zta: Implications for therapy of EBV associated tumors

  2009cited by this paper
• AP-1 homolog BZLF1 of Epstein–Barr virus has two essential functions dependent on the epigenetic state of the viral genome

  2009cited by this paper
• Aspirin induces lytic cytotoxicity in Epstein‐Barr virus‐positive cells

  2008cited by this paper
• Cancer chemoprevention and chemotherapy: dietary polyphenols and signalling pathways.

  2008cited by this paper
• Role of Epstein-Barr virus encoded latent membrane protein 1 in the carcinogenesis of nasopharyngeal carcinoma.

  2007cited by this paper
• Spectrum of Epstein-Barr virus-associated diseases.

  2006cited by this paper
• Oncogenic Activity of Epstein-Barr Virus Latent Membrane Protein 1 (LMP-1) Is Down-Regulated by Lytic LMP-1

  2006cited by this paper
• Epstein-Barr Virus Transforming Protein LMP1 Plays a Critical Role in Virus Production

  2005cited by this paper
• Latent and lytic Epstein‐Barr virus replication strategies

  2005influential reference
• Effect of EBV LMP1 targeted DNAzymes on cell proliferation and apoptosis

  2005cited by this paper
• [Epigallocatechin-3-gallate interferes with EBV-encoding AP-1 signal transduction pathway].

  2004cited by this paper
• Upregulation of LMP1 Expression by Histone Deacetylase Inhibitors in an EBV Carrying NPC Cell Line

  2004cited by this paper
• Induction of Epstein-Barr Virus Latent Membrane Protein 1 by a Lytic Transactivator Rta

  2004influential reference
• Epstein–Barr virus: 40 years on

  2004cited by this paper
• Latent Membrane Protein 1 Inhibits Epstein-Barr Virus Lytic Cycle Induction and Progress via Different Mechanisms

  2003influential reference
• Epstein–Barr virus and oncogenesis: from latent genes to tumours

  2003cited by this paper
• Inhibition of Epstein-Barr virus lytic cycle by (-)-epigallocatechin gallate.

  2003cited by this paper
• Epstein-Barr Virus Latent Membrane Protein 1: Structure and Functions

  2003cited by this paper
• Epstein-Barr virus latent membrane protein-1 (LMP-1) and lytic LMP-1 localization in plasma membrane-derived extracellular vesicles and intracellular virions.

  2003cited by this paper
• Production of bioactive triterpenes by Eriobotrya japonica calli.

  2002cited by this paper
• The significance of LMP1 expression in nasopharyngeal carcinoma.

  2002cited by this paper
• Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

  2001cited by this paper
• Control of Epstein–Barr virus reactivation by activated CD40 and viral latent membrane protein 1

  2001cited by this paper
• Activation of TRAF5 and TRAF6 Signal Cascades Negatively Regulates the Latent Replication Origin of Epstein-Barr Virus through p38 Mitogen-Activated Protein Kinase

  2001cited by this paper
• Quantitative Analysis of Epstein‐Barr Virus DNA in Plasma and Serum

  2001influential reference
• Quantitative analysis of circulating cell‐free Epstein–Barr virus (EBV) DNA levels in patients with EBV‐associated lymphoid malignancies

  2000influential reference
• Detection of Epstein-Barr virus DNA in hepatocellular carcinoma tissues from hepatitis C-positive patients.

  2000cited by this paper
• Requirement for Cell-to-Cell Contact in Epstein-Barr Virus Infection of Nasopharyngeal Carcinoma Cells and Keratinocytes

  1999cited by this paper
• Cationic porphyrins: novel delivery vehicles for antisense oligodeoxynucleotides.

  1998cited by this paper
• Inhibition of in vitro proliferation of Epstein Barr Virus infected B cells by an antisense oligodeoxynucleotide targeted against EBV latent membrane protein LMP1

  1997cited by this paper
• Up regulation of the Epstein-Barr virus (EBV)-encoded membrane protein LMP in the Burkitt's lymphoma line Daudi after exposure to n-butyrate and after EBV superinfection

  1990cited by this paper
• Hodgkin's disease and Epstein-Barr virus. Altered antibody pattern before diagnosis.

  1989cited by this paper
• The truncated form of the Epstein-Barr virus latent-infection membrane protein expressed in virus replication does not transform rodent fibroblasts

  1988cited by this paper
• Monoclonal antibodies to the latent membrane protein of Epstein-Barr virus reveal heterogeneity of the protein and inducible expression in virus-transformed cells.

  1987cited by this paper
• Enhancement of Epstein-Barr virus membrane protein (LMP) expression by serum, TPA, or n-butyrate in latently infected Raji cells.

  1987influential reference
• Final case reporting from the ugandan prospective study of the relationship between ebv and burktit's lymphoma

  1982cited by this paper
• Release of infectious Epstein-Barr virus by transformed marmoset leukocytes.

  1973cited by this paper

• No citing papers are available for this paper.